DK0912601T3 - Suppression af immunrespons ved inhibering af cathepsin S - Google Patents

Suppression af immunrespons ved inhibering af cathepsin S

Info

Publication number
DK0912601T3
DK0912601T3 DK97921360T DK97921360T DK0912601T3 DK 0912601 T3 DK0912601 T3 DK 0912601T3 DK 97921360 T DK97921360 T DK 97921360T DK 97921360 T DK97921360 T DK 97921360T DK 0912601 T3 DK0912601 T3 DK 0912601T3
Authority
DK
Denmark
Prior art keywords
class
cathepsin
mhc
methods
immune response
Prior art date
Application number
DK97921360T
Other languages
English (en)
Other versions
DK0912601T4 (da
Inventor
Hidde L Ploegh
Harold A Chapman
Richard J Riese
Paula R Wolf
Matthew S Bogyo
Original Assignee
Massachusetts Inst Technology
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21786243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0912601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology, Brigham & Womens Hospital filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK0912601T3 publication Critical patent/DK0912601T3/da
Publication of DK0912601T4 publication Critical patent/DK0912601T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK97921360T 1996-04-22 1997-04-22 Suppression af immunrespons ved inhibering af cathepsin S DK0912601T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1810096P 1996-04-22 1996-04-22
PCT/US1997/006865 WO1997040066A1 (en) 1996-04-22 1997-04-22 Suppression of immune response via inhibition of cathepsin s

Publications (2)

Publication Number Publication Date
DK0912601T3 true DK0912601T3 (da) 2004-03-29
DK0912601T4 DK0912601T4 (da) 2009-03-09

Family

ID=21786243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97921360T DK0912601T4 (da) 1996-04-22 1997-04-22 Suppression af immunrespons ved inhibering af cathepsin S

Country Status (12)

Country Link
US (4) US6608030B1 (da)
EP (1) EP0912601B2 (da)
JP (1) JP2000509376A (da)
AT (1) ATE255126T1 (da)
AU (1) AU723447B2 (da)
CA (1) CA2251714A1 (da)
DE (1) DE69726426T3 (da)
DK (1) DK0912601T4 (da)
ES (1) ES2208898T5 (da)
NZ (1) NZ332390A (da)
PT (1) PT912601E (da)
WO (1) WO1997040066A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204279B1 (en) * 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
WO1999037667A1 (en) * 1998-01-23 1999-07-29 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
EP1076723A2 (en) * 1998-06-04 2001-02-21 Reprogen, Inc. Use of cathepsin s in the diagnosis and treatment of endometriosis
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU2001284823B2 (en) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
DE60126286T2 (de) 2000-08-14 2007-11-15 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
DK1315966T3 (da) 2000-09-06 2008-01-02 Ortho Mcneil Pharm Inc Fremgangsmåde til overvågning af virkningen af cathepsin S-inhibitorer
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US6780985B2 (en) * 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
JP2003287139A (ja) * 2002-03-29 2003-10-10 Uchiyama Mfg Corp ガスケット
US7101880B2 (en) * 2002-06-24 2006-09-05 Schering Aktiengesellschaft Peptidic compounds as cysteine protease inhibitors
US7319016B1 (en) 2002-08-23 2008-01-15 Takeda San Diego, Inc. Crystallization of cathepsin S
AU2004233582B2 (en) * 2003-04-28 2008-05-15 Novartis Ag Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
WO2005028424A1 (en) * 2003-09-23 2005-03-31 Merck Frosst Canada Ltd. Whole cell assay involving cathepsin s
EP1694357A1 (en) * 2003-12-11 2006-08-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
US20070105892A1 (en) * 2003-12-23 2007-05-10 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
BRPI0506494A (pt) * 2004-01-30 2007-02-13 Schering Ag compostos de silinano como inibidores de cisteìna protease
NZ571985A (en) * 2006-04-10 2012-01-12 Fusion Antibodies Ltd Therapy targeting Cathepsin S
WO2009014702A2 (en) * 2007-07-25 2009-01-29 Board Of Regents, The University Of Texas System Cd74 for use in the treatment of cancer and liver toxicity
EP2216047A4 (en) * 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
KR20110101215A (ko) * 2008-12-19 2011-09-15 메디버 유케이 리미티드 시스테인 프로테아제 억제제
EP2582660B1 (en) * 2010-06-16 2015-07-22 Medivir UK Ltd New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181925T1 (de) 1991-05-23 1999-07-15 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
WO1994004557A1 (en) 1992-08-11 1994-03-03 President And Fellows Of Harvard College Immunomodulatory peptides
DE69321087T2 (de) 1992-12-25 1999-05-20 Mitsubishi Chem Corp Alpha-aminoketon Derivate
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
AU713492B2 (en) 1995-03-24 1999-12-02 Axys Pharmaceuticals, Inc. Reversible protease inhibitors

Also Published As

Publication number Publication date
DK0912601T4 (da) 2009-03-09
DE69726426T2 (de) 2004-09-16
PT912601E (pt) 2004-04-30
US20050080010A1 (en) 2005-04-14
ATE255126T1 (de) 2003-12-15
CA2251714A1 (en) 1997-10-30
EP0912601B1 (en) 2003-11-26
US20050095248A1 (en) 2005-05-05
EP0912601B2 (en) 2008-11-05
US6608030B1 (en) 2003-08-19
AU723447B2 (en) 2000-08-24
US20030166534A1 (en) 2003-09-04
DE69726426D1 (de) 2004-01-08
AU2741897A (en) 1997-11-12
EP0912601A1 (en) 1999-05-06
ES2208898T5 (es) 2009-04-16
US7285525B2 (en) 2007-10-23
NZ332390A (en) 2000-07-28
WO1997040066A1 (en) 1997-10-30
JP2000509376A (ja) 2000-07-25
ES2208898T3 (es) 2004-06-16
DE69726426T3 (de) 2009-09-10
US7427591B2 (en) 2008-09-23

Similar Documents

Publication Publication Date Title
DK0912601T4 (da) Suppression af immunrespons ved inhibering af cathepsin S
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
DK1731912T3 (da) Fremgangmåde til peptidselektion
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
GR3021421T3 (en) Compositions for use in a method for treating a human suffering from multiple sclerosis
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
Schwartz et al. External Factors, Produced by Growing Nerves, Trigger a Regenerative Response in a Non-Regenerative Central Nervous System: Purification and Mode of Action